Regorafenib and Cetuximab in Patients With Advanced Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 19, 2014

Primary Completion Date

March 27, 2020

Study Completion Date

March 27, 2020

Conditions
Advanced Cancers
Interventions
DRUG

Regorafenib

"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."

DRUG

Cetuximab

"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."

BEHAVIORAL

Questionnaire

Symptom questionnaire completed at each study visit.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT02095054 - Regorafenib and Cetuximab in Patients With Advanced Malignancy | Biotech Hunter | Biotech Hunter